Imugene's Azer-Cel Hits 82% Response Rate in Lymphoma Trial

MT Newswires Live12-01

Imugene (ASX:IMU) said that its phase 1b trial of azercabtagene zapreleucel (azer-cel) in patients with relapsed or refractory diffuse large B-cell lymphoma showed an 82% overall response rate, with most patients responding within one to three months, according to a Monday filing with the Australian bourse.

The durability of responses is improving, particularly in patients treated with azer-cel alongside interleukin-2, per the filing.

Azer-cel, an allogeneic "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy, aims to overcome the access, manufacturing, and timing limitations of autologous CAR T-cell treatments, the filing said.

The phase 1b trial is continuing at 10 sites in the US, with up to six sites planned in Australia after the first Australian patient at Royal Prince Alfred Hospital achieved a complete response, the filing added.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588174581?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 13:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588174581","market":"hk","top_or_hot":-1,"title":"Imugene's Azer-Cel Hits 82% Response Rate in Lymphoma Trial","media":"MT Newswires Live","content":"<html><body><p> Imugene (ASX:IMU) said that its phase 1b trial of azercabtagene zapreleucel (azer-cel) in patients with relapsed or refractory diffuse large B-cell lymphoma showed an 82% overall response rate, with most patients responding within one to three months, according to a Monday filing with the Australian bourse.</p><p>The durability of responses is improving, particularly in patients treated with azer-cel alongside interleukin-2, per the filing.</p><p>Azer-cel, an allogeneic \"off-the-shelf\" chimeric antigen receptor (CAR) T-cell therapy, aims to overcome the access, manufacturing, and timing limitations of autologous CAR T-cell treatments, the filing said.</p><p>The phase 1b trial is continuing at 10 sites in the US, with up to six sites planned in Australia after the first Australian patient at Royal Prince Alfred Hospital achieved a complete response, the filing added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Imugene's Azer-Cel Hits 82% Response Rate in Lymphoma Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImugene's Azer-Cel Hits 82% Response Rate in Lymphoma Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-01 13:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Imugene (ASX:IMU) said that its phase 1b trial of azercabtagene zapreleucel (azer-cel) in patients with relapsed or refractory diffuse large B-cell lymphoma showed an 82% overall response rate, with most patients responding within one to three months, according to a Monday filing with the Australian bourse.</p><p>The durability of responses is improving, particularly in patients treated with azer-cel alongside interleukin-2, per the filing.</p><p>Azer-cel, an allogeneic \"off-the-shelf\" chimeric antigen receptor (CAR) T-cell therapy, aims to overcome the access, manufacturing, and timing limitations of autologous CAR T-cell treatments, the filing said.</p><p>The phase 1b trial is continuing at 10 sites in the US, with up to six sites planned in Australia after the first Australian patient at Royal Prince Alfred Hospital achieved a complete response, the filing added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588174581","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588174581","pubTimestamp":1764565213,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Imugene  said that its phase 1b trial of azercabtagene zapreleucel  in patients with relapsed or refractory diffuse large B-cell lymphoma showed an 82% overall response rate, with most patients responding within one to three months, according to a Monday filing with the Australian bourse.The durability of responses is improving, particularly in patients treated with azer-cel alongside interleukin-2, per the filing.Azer-cel, an allogeneic \"off-the-shelf\" chimeric antigen receptor  T-cell therapy, aims to overcome the access, manufacturing, and timing limitations of autologous CAR T-cell treatments, the filing said.The phase 1b trial is continuing at 10 sites in the US, with up to six sites planned in Australia after the first Australian patient at Royal Prince Alfred Hospital achieved a complete response, the filing added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","IMU.AU":"IMUGENE LTD","BK4022":"陆运","CAR":"安飞士","BK4230":"旅客陆运","BK7503":"科技股","CAR.AU":"CAR GROUP LTD","BK7002":"互动媒体与服务","BK7067":"生物科技"},"translate_title":"Imugene的Azer-Cel在淋巴瘤试验中达到82%的缓解率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMU.AU":1,"CAR":1,"CAR.AU":1},"content_text":"Imugene (ASX:IMU) said that its phase 1b trial of azercabtagene zapreleucel (azer-cel) in patients with relapsed or refractory diffuse large B-cell lymphoma showed an 82% overall response rate, with most patients responding within one to three months, according to a Monday filing with the Australian bourse.The durability of responses is improving, particularly in patients treated with azer-cel alongside interleukin-2, per the filing.Azer-cel, an allogeneic \"off-the-shelf\" chimeric antigen receptor (CAR) T-cell therapy, aims to overcome the access, manufacturing, and timing limitations of autologous CAR T-cell treatments, the filing said.The phase 1b trial is continuing at 10 sites in the US, with up to six sites planned in Australia after the first Australian patient at Royal Prince Alfred Hospital achieved a complete response, the filing added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588174581","isCrawlerRequest":true}